Orchestra BioMed Holdings, Inc. (OBIO) Profit Margin
Orchestra BioMed Holdings, Inc. (OBIO) net profit margin by fiscal period. Analyze profit margins in Excel with MarketXLS.
Profit Margin Data
| Period | Net Profit Margin |
|---|---|
| 2020-12-31 | N/A |
| 2021-12-31 | N/A |
| 2022-12-31 | -951.26% |
| 2023-12-31 | -1779.71% |
| 2024-12-31 | -2313.27% |
| 2025-12-31 | -157.40% |
How OBIO compares with sector peers
| Symbol | Company | Net profit margin (latest fiscal year) |
|---|---|---|
| SPRO | Spero Therapeutics Inc. | 12.83% |
| IDYA | IDEAYA Biosciences Inc. | -51.99% |
| RGNX | REGENXBIO Inc. | -113.75% |
| VYGR | Voyager Therapeutics Inc. | -296.53% |
| OCUL | Ocular Therapeutix Inc. | -511.90% |
These are five companies in the same sector as OBIO with a comparable annual net profit margin. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Orchestra BioMed Holdings, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Profit_Margin("OBIO", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | OBIO | $4.41 | +0.00% | 0.23M |
| 3 | ||||
| 4 | ||||
| 5 |